Nilotinib is effective in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blastic phase

F. J. Giles*, H. M. Kantarjian, P. D. Le Coutre, M. Baccarani, F. X. Mahon, R. E. Blakesley, N. J. Gallagher, K. Gillis, S. L. Goldberg, R. A. Larson, A. Hochhaus, O. G. Ottmann

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

60 Scopus citations

Abstract

Nilotinib is a selective inhibitor of BCR-ABL approved for use in newly diagnosed and imatinib-resistant or-intolerant patients with chronic myeloid leukemia (CML) in chronic phase. In this study, 400 mg of nilotinib was administered twice daily to the patients with myeloid (MBP, n105) or lymphoid blastic phase (LBP, n31) CML. After a minimum follow-up of 24 months, major hematologic responses were observed in 60% (MBP) and 59% (LBP) of patients. Major cytogenetic responses (MCyR) were attained in 38% (MBP) and 52% (LBP) of patients; and complete cytogenetic responses in 30% and 32%, respectively. Median duration of MCyR was 10.8 (MBP) and 3.2 months (LBP). Median overall survival was 10.1 (MBP) and 7.9 (LBP) months with 12-and 24-month survival of 42% (MBP 44%, LBP 35%) and 27% (MBP 32%, LBP 10%), respectively. Twelve MBP patients and two LBP patients received subsequent stem cell transplantation. Myelosuppression was frequent, with grade 3/4 neutropenia, thrombocytopenia, and anemia in 68%, 63% and 47% of patients, respectively. Grade 3/4 hypophosphatemia, hyperbilirubinemia and lipase elevation were observed in 15%, 11% and 11% of patients, respectively. Nilotinib has significant efficacy in patients with BP CML, but given the limited long-term survival of these patients, novel agents are needed.

Original languageEnglish (US)
Pages (from-to)959-962
Number of pages4
JournalLeukemia
Volume26
Issue number5
DOIs
StatePublished - May 2012

Keywords

  • BCR-ABL
  • Nilotinib
  • blastic phase
  • chronic myeloid leukemia
  • imatinib resistance
  • mutations

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Nilotinib is effective in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blastic phase'. Together they form a unique fingerprint.

Cite this